AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24612448 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyesi cataract simulator training programme (Group A) - completed once a week for 4 weeks
Number of subjects: 20
Study 24612448 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) - completed training once a week at the first and last week
Number of subjects: 20
Study 22277556 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (1.6 mg/d for 16 wk)
Number of subjects: 31
Study 22277556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 19281446 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Level of Replacement Therapy
Number of subjects: 0
Study 19281446 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Level of Replacement Therapy
Number of subjects: 0
Study 17685917 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with routine infusions of factor VIII (FVIII) concentrate
Number of subjects: 0
Study 17685917 — intervention group
Group type: COMPARATOR
Intervention: On-demand FVIII treatment
Number of subjects: 0
Study 17685917 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating dose frequency of prophylaxis
Number of subjects: 0
Study 15937369 — intervention group
Group type: EXPERIMENTAL
Intervention: North Indian diet (high calorie, high fat)
Number of subjects: 9
Study 15937369 — intervention group
Group type: EXPERIMENTAL
Intervention: South Indian diet (low calorie, low fat)
Number of subjects: 9
Study 15937369 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 9
Study 12184540 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 31
Study 12184540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9641318 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous otoacoustic emissions (SOAEs) measured by placing a small microphone at the entrance to the ear canal, analyzed acoustically with external tones.
Number of subjects: 0
Study 9641318 — intervention group
Group type: EXPERIMENTAL
Intervention: External tones presented as 250 ms pulses, twice a second.
Number of subjects: 0
Study 9641318 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of aspirin by one subject.
Number of subjects: 0
Study 8086551 — intervention group
Group type: EXPERIMENTAL
Intervention: iv clindamycin (900 mg every 8 hours for 10 days, then oral clindamycin (450 mg every 6 hours for 11 days) + oral primaquine (30 mg once daily)
Number of subjects: 60
Study 8086551 — intervention group
Group type: EXPERIMENTAL
Intervention: oral clindamycin (600 mg every 8 hours) + oral primaquine (30 mg once daily)
Number of subjects: 60
Study 31857511 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV-guided fluid therapy (group S)
Number of subjects: 120
Study 31857511 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 120
Study 27598342 — intervention group
Group type: EXPERIMENTAL
Intervention: Local muscle vibration treatment (300 Hz, 30 minutes, 3 times per week for 12 sessions)
Number of subjects: 32
Study 27598342 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 32
Study 27571294 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 387
Study 27571294 — intervention group
Group type: EXPERIMENTAL
Intervention: Light touch (LT)
Number of subjects: 387
Study 27571294 — intervention group
Group type: COMPARATOR
Intervention: Conventional care only (CCO)
Number of subjects: 387
Study 24960439 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for the Treatment of Emotional Disorders in Adolescence (UP-A)
Number of subjects: 59
Study 22295884 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (80 mg)
Number of subjects: 100
Study 22295884 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg)
Number of subjects: 100
Study 19856067 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin 500 mg once daily
Number of subjects: 164
Study 17084792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone medical maintenance (MMM) at the methadone maintenance program
Number of subjects: 92
Study 17084792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone medical maintenance (MMM) at a physician's office
Number of subjects: 92
Study 17084792 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 92
Study 15574068 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-set resistance training
Number of subjects: 71
Study 15574068 — intervention group
Group type: COMPARATOR
Intervention: Single-set resistance training
Number of subjects: 71
Study 14728019 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer for primary angioplasty without fibrinolytic treatment
Number of subjects: 0
Study 14728019 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aggressive approach
Number of subjects: 0
Study 14728019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital ambulance triage to interventional centers
Number of subjects: 0
Study 9236500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 50 micrograms
Number of subjects: 480
Study 9236500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 100 micrograms
Number of subjects: 480
Study 9236500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 200 micrograms
Number of subjects: 480
Study 9236500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 800 micrograms
Number of subjects: 480
Study 9236500 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 480
Study 8422174 — intervention group
Group type: COMPARATOR
Intervention: Group C: 12 mg/m2 of MMC on the day of operation, followed by 6 mg/m2 every 2 months for 6 times, and 600 mg/body of UFT continuously administered every day for 1 year.
Number of subjects: 556
Study 8422174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: 400 mg/body of UFT every day and the same amount of MMC as Group C.
Number of subjects: 556
Study 8422174 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT dosage per body weight (kg) of 8-12 mg/kg.
Number of subjects: 556
Study 2446056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg b.i.d. after 2 weeks of 20 mg b.i.d.)
Number of subjects: 117
Study 2446056 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg N retard b.i.d.)
Number of subjects: 117
Study 30566439 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear projection method for gene expression data
Number of subjects: 3571
Study 30566439 — intervention group
Group type: EXPERIMENTAL
Intervention: Projection coordinates as covariates in eQTL analysis
Number of subjects: 3571
Study 27488574 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP XR-ODT (18.8 mg)
Number of subjects: 42
Study 27488574 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP XR-ODT (18.8 mg) with food
Number of subjects: 42
Study 27488574 — intervention group
Group type: COMPARATOR
Intervention: MAS ER (30 mg)
Number of subjects: 42
Study 25376790 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg daily on days 1 through 28 of each 4-week cycle
Number of subjects: 38
Study 23760573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagatose (5 g)
Number of subjects: 85
Study 23760573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagatose (10 g)
Number of subjects: 85
Study 23760573 — intervention group
Group type: COMPARATOR
Intervention: Sucralose-erythritol drink (placebo)
Number of subjects: 85
Study 20806849 — intervention group
Group type: EXPERIMENTAL
Intervention: Time management training
Number of subjects: 71
Study 20806849 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 71
Study 18213452 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin delayed release tablet (20 mg)
Number of subjects: 0
Study 18213452 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin immediate release capsule (20 mg)
Number of subjects: 0
Study 18213452 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin immediate release tablet Zocor (20 mg)
Number of subjects: 0
Study 15760500 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed (35 degrees C) and humidified (95%) CO2
Number of subjects: 30
Study 15760500 — intervention group
Group type: COMPARATOR
Intervention: Standard (dry, room temperature) CO2
Number of subjects: 30
Study 15760500 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain scores and narcotic usage
Number of subjects: 30
Study 12612979 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin in addition to ACE inhibitors and ARBs
Number of subjects: 56
Study 12612979 — intervention group
Group type: COMPARATOR
Intervention: No atorvastatin in addition to ACE inhibitors and ARBs
Number of subjects: 56
Study 10697305 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg once daily for 6 weeks
Number of subjects: 22
Study 10697305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8612120 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of astemizole
Number of subjects: 263
Study 8612120 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of cetirizine
Number of subjects: 263
Study 8612120 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cetirizine
Number of subjects: 263
Study 8612120 — intervention group
Group type: COMPARATOR
Intervention: Control group (astemizole)
Number of subjects: 263
Study 2017020 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation force of 20 N
Number of subjects: 24
Study 2017020 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation force of 50 N
Number of subjects: 24
Study 2017020 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation force of 100 N
Number of subjects: 24
Study 2017020 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular velocity of 45 degrees.s-1
Number of subjects: 24
Study 2017020 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular velocity of 135 degrees.s-1
Number of subjects: 24
Study 2017020 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric muscle actions at 80 degrees knee flexion
Number of subjects: 24
Study 2017020 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric muscle actions at 20 degrees flexion
Number of subjects: 24
Study 10250813 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Management Plan (IMP)
Number of subjects: 432
Study 29117764 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM + EC (counseling and in advance provision of one packet of 0.75‐mg LNG‐ECPs)
Number of subjects: 2708
Study 29117764 — intervention group
Group type: COMPARATOR
Intervention: LAM-only (adequate lactational amenorrhea method counseling)
Number of subjects: 2708
Study 29176387 — intervention group
Group type: EXPERIMENTAL
Intervention: CODJ-G (complex COD and plyometric protocol)
Number of subjects: 21
Study 29176387 — intervention group
Group type: COMPARATOR
Intervention: COD-G (isolated COD protocol)
Number of subjects: 21
Study 27569118 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-calorie alternate-day fasting (ADF)
Number of subjects: 26
Study 27569118 — intervention group
Group type: COMPARATOR
Intervention: Moderate daily caloric restriction (CR)
Number of subjects: 26
Study 25040146 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduction of angiotensin inhibitor dose (n=30)
Number of subjects: 46
Study 25040146 — intervention group
Group type: COMPARATOR
Intervention: Standard basal dose of angiotensin inhibitors (n=16)
Number of subjects: 46
Study 25040146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 23074122 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol
Number of subjects: 62
Study 23074122 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia with desflurane
Number of subjects: 62
Study 20706157 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric (PL) training
Number of subjects: 36
Study 20706157 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympic weight lifting (OL) training
Number of subjects: 36
Study 20706157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weight lifting + plyometric (WP) training
Number of subjects: 36
Study 20706157 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 36
Study 17126339 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐LH (150 IU per day from day 8 of gonadotropin stimulation)
Number of subjects: 40
Study 17126339 — intervention group
Group type: COMPARATOR
Intervention: Control (r‐FSH alone)
Number of subjects: 40
Study 14748937 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, high-sodium diet (90 g/d protein, 180 mmol/d Na)
Number of subjects: 24
Study 14748937 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (70 g/d protein, 65 mmol/d Na)
Number of subjects: 24
Study 11167954 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 3722
Study 11167954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3722
Study 9606842 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Number of subjects: 4
Study 9606842 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C
Number of subjects: 4
Study 9606842 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 4
Study 7939431 — intervention group
Group type: COMPARATOR
Intervention: Oral teicoplanin 100 mg twice daily for 7 days (BID group)
Number of subjects: 92
Study 7939431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral teicoplanin 50 mg 4 times daily for 3 days, followed by 100 mg twice daily for 4 days (QID group)
Number of subjects: 92
Study 7939431 — intervention group
Group type: EXPERIMENTAL
Intervention: QID group
Number of subjects: 92
Study 3283457 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with tamoxifen
Number of subjects: 539
Study 3283457 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant tamoxifen
Number of subjects: 539
Study 3283457 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptor-positive tumors
Number of subjects: 539
Study 3283457 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptor-negative tumors
Number of subjects: 539
Study 3283457 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal patients
Number of subjects: 539
Study 29365125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentatherapy (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir, and maraviroc)
Number of subjects: 50
Study 29365125 — intervention group
Group type: COMPARATOR
Intervention: Tritherapy (darunavir/ritonavir, tenofovir disoproxil fumarate, and emtricitabine)
Number of subjects: 50
Study 27079708 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirtan Kriya Meditation (KK)
Number of subjects: 60
Study 27079708 — intervention group
Group type: COMPARATOR
Intervention: Music Listening (ML)
Number of subjects: 60
Study 24760352 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 0
Study 24760352 — intervention group
Group type: COMPARATOR
Intervention: 3.1% sodium chloride solution (hypertonic saline)
Number of subjects: 0
Study 23107971 — intervention group
Group type: COMPARATOR
Intervention: Standard dose gemcitabine (1,000 mg/m2) with carboplatin (AUC 5)
Number of subjects: 60
Study 23107971 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prolonged infusion gemcitabine (350 mg/m2) with carboplatin (AUC 5)
Number of subjects: 60
Study 20122038 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH intervention (individual risk profiles, nine in-home sessions, three telephone sessions over 6 months)
Number of subjects: 495
Study 20122038 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group (two brief 'check-in' telephone calls during 6 months)
Number of subjects: 495
Study 18310162 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized physician order entry (CPOE)
Number of subjects: 627
Study 18310162 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-implementation of CPOE)
Number of subjects: 627
Study 15802773 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH)
Number of subjects: 0
Study 15802773 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 0
Study 12592896 — intervention group
Group type: EXPERIMENTAL
Intervention: General carbon dioxide baths and therapeutic exercises
Number of subjects: 0
Study 12592896 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10235192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg, clarithromycin 500 mg, and amoxicillin 1 g, all given b.i.d. for 10 days
Number of subjects: 77
Study 10235192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate, amoxicillin, and clarithromycin (10-day therapy)
Number of subjects: 77
Study 8557125 — intervention group
Group type: EXPERIMENTAL
Intervention: Agonist administered irrespective of cycle phase
Number of subjects: 557
Study 1758931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic water plus vodka (approximately .05% blood alcohol level)
Number of subjects: 40
Study 1758931 — intervention group
Group type: COMPARATOR
Intervention: Tonic water only
Number of subjects: 40
Study 7078423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 5 mg/day
Number of subjects: 63
Study 7078423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 30442422 — intervention group
Group type: COMPARATOR
Intervention: Female caregivers
Number of subjects: 13
Study 28359339 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg for 2 weeks before surgery
Number of subjects: 30
Study 28359339 — intervention group
Group type: COMPARATOR
Intervention: No change to current statin therapy
Number of subjects: 30
Study 26180476 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged posterior YAG capsulotomy
Number of subjects: 83
Study 26180476 — intervention group
Group type: COMPARATOR
Intervention: Conventional circular YAG capsulotomy
Number of subjects: 83
Study 25113389 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D strain analysis
Number of subjects: 50
Study 25113389 — intervention group
Group type: COMPARATOR
Intervention: 2D and 3D strain analysis
Number of subjects: 50
Study 22015451 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rasburicase (0.15 mg/kg)
Number of subjects: 80
Study 22015451 — intervention group
Group type: COMPARATOR
Intervention: Daily dosing of rasburicase for 5 days
Number of subjects: 80
Study 19509098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene, metformin, or combination of both for up to six cycles
Number of subjects: 626
Study 17244248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a monotherapy (9 MUI/day for 4 weeks and then 3 MUI/3 t.i.w. for 44 weeks)
Number of subjects: 378
Study 17244248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a + Amantadine (100 mg twice daily for 48 weeks)
Number of subjects: 378
Study 17244248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a + Ribavirin (1000-1200 mg)
Number of subjects: 378
Study 17244248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a + Amantadine + Ribavirin
Number of subjects: 378
Study 15195760 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐PET system
Number of subjects: 74
Study 15195760 — intervention group
Group type: COMPARATOR
Intervention: d‐PET system
Number of subjects: 74
Study 12271419 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-sestamibi/(18)F-FDG DISA SPET
Number of subjects: 19
Study 12271419 — intervention group
Group type: COMPARATOR
Intervention: (13)N-ammonia/(18)F-FDG PET
Number of subjects: 19
Study 9830234 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release 5-ISMN 60 mg once daily
Number of subjects: 44
Study 9830234 — intervention group
Group type: COMPARATOR
Intervention: Conventional 5-ISMN 20 mg twice daily
Number of subjects: 44
Study 8132132 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 to 10mg oral, given at bedtime)
Number of subjects: 15
Study 3777565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus method (Group A)
Number of subjects: 16
Study 3777565 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion method (Group B)
Number of subjects: 16
Study 3777565 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 16
Study 29571808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy CTPA (Group 1: 80/Sn140 kVp, 89/38 mAs)
Number of subjects: 62
Study 29571808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy CTPA (Group 2: 100/Sn140 kVp, 89/76 mAs)
Number of subjects: 62
Study 29571808 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-energy CTPA (Group 3: 120 kVp, 110 mAs)
Number of subjects: 62
Study 29571808 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy CTPA (Group 1)
Number of subjects: 62
Study 29571808 — intervention group
Group type: COMPARATOR
Intervention: Single-energy CTPA (Group 3)
Number of subjects: 62
Study 29571808 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy CTPA (Group 2)
Number of subjects: 62
Study 27112909 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video (BV)
Number of subjects: 179
Study 27112909 — intervention group
Group type: EXPERIMENTAL
Intervention: CCO-CPR class
Number of subjects: 179
Study 27112909 — intervention group
Group type: COMPARATOR
Intervention: Control (sham video)
Number of subjects: 179
Study 24851689 — intervention group
Group type: COMPARATOR
Intervention: PCV‐VG group
Number of subjects: 30
Study 22612306 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSCT
Number of subjects: 200
Study 22612306 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX
Number of subjects: 200
Study 22612306 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX + MBSCT
Number of subjects: 200
Study 20657853 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subgallate paste
Number of subjects: 10
Study 20657853 — intervention group
Group type: COMPARATOR
Intervention: Moistened gauze pressure
Number of subjects: 10
Study 18562775 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI/High-GL meal (H-H) - Carbohydrate content 65%, GI 79, GL 82
Number of subjects: 8